News from ACIU

AC Immune receives FDA Fast Track Designation for anti-Abeta active immunotherapy ACI-24.060 to treat Alzheimer’s

Read our latest announcement.

Read more

Targeting misfolded self-proteins

Pioneering precision medicine for neurodegeneration

Monitoring patients’ specific proteinopathies, enables well-timed selection of the most appropriate therapeutic(s).

Read More

Prevention through early and safe intervention

Developing vaccine strategies to prevent Alzheimer's and Parkinson's disease

Neurodegeneration is a slow, silent pandemic. It is a moral and economic imperative to address it. Preserving neurons and preventing disease is the most promising strategy.

Read more

AC Immune’s technology platforms

Morphomer® and Supraantigen® platforms deliver best-in-class small molecules and biologics

Discover the technologies that generated our differentiated pipeline of diagnostic and therapeutic candidates

Read more

Latest news from ACIU

AC Immune partner Life Molecular Imaging initiates Phase 3 study of Tau-PET diagnostic PI-2620 for Alzheimer’s disease

Read our latest announcement.

Read more

AC Immune is pioneering new ways to diagnose, treat and prevent neurodegeneration

AC Immune SA, a clinical-stage biopharmaceutical company, is a global leader in developing precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and certain rare indications. We are addressing the social and economic imperative created by the growing incidence of neurodegenerative diseases.

Our deep knowledge and cutting-edge technology platforms are the engines for our diverse pipeline of clinical and preclinical product candidates including vaccines, antibodies, small molecule drugs and diagnostic agents. We have pioneered scientific and clinical advances in the understanding and treatment of neurodegeneration.

Our scientific leadership, technologies and pipeline have been validated by our partnerships with global pharmaceutical leaders: Genentech, a member of the Roche group, Janssen Pharmaceuticals, and Eli Lilly and Co.

AC Immune is shaping the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine.

Latest News

Facts & Figures

>50 Million

People worldwide living
with Dementia

>$1 Trillion

Global annual
Cost of Dementia

>6 Million

People worldwide living
with Parkinson's

>8 Million

People living with different
NeuroOrphan diseases in the U.S.

Addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases


Our clinical stage pipeline uniquely integrates diagnostic and therapeutic candidates as well as different treatment modalities (such as antibodies, vaccines and small molecule drugs) against the most promising validated therapeutic targets.

Pioneering Precision Medicine

AC Immune develops the tools to enable detection and clearance of pathological proteins underlying neurodegenerative diseases. Identifying and targeting these misfolded proteins and related pathways in each patient will be key to achieving best possible efficacy.

AC Immune | Pioneering Precision Medicine for neurodegenerative diseases